Tuesday 02 June 2020

Faculté de Pharmacie
3, rue du Professeur Laguesse
BP83 - 59006 - Lille Cedex
Tél. : +33 (0)3 20 96 40 40
Fax : +33 (0)3 20 95 90 09
mailContact

Director of the INSERM U1008: Prof. Dr. Juergen SIEPMANN

Université de Lille
College of Pharmacy
3, rue du Professeur Laguesse
59006 Lille, France

Tel:  +33-3-20.96.47.08
Télécharger le fichierjuergen.siepmann(at)univ-lille.fr

Short CV

Juergen Siepmann studied Pharmacy and did his Ph.D. at the Freie Universitaet Berlin, Germany. Since 2004 he is Professor of Pharmaceutical Technology at the University of Lille, France.

In 2006 Prof. Siepmann created the “Young research group: Controlled Drug Delivery Systems”, which became the “INSERM research group: Advanced Drug Delivery Systems” in 2010 (INSERM = French National Institute of Health and Medical Research). The team currently counts about 50 scientists: 9 professors, 6 senior lecturers, 7 technical/administrative staff, and about 20 post-docs/PhD students & 10 master students.

Prof. Siepmann’s research focuses on controlled drug delivery systems, in particular on the elucidation of the underlying mass transport phenomena, mathematical modeling and the optimization of the devices.

So far, he published his work in more than 180 articles in international scientific journals, 325 poster and 140 oral presentations at national and international scientific meetings. He is editor of 3 books, theme editor of 9 special issues, inventor of 9 patents and author of 17 book chapters.

His awards include the “APV-Prize for the outstanding doctoral thesis in Pharmaceutical Sciences from the years 1998/99”, a Marie Curie Individual Post-Doctoral Fellowship and the “2012 APV Research Award for Outstanding Achievements in the Pharmaceutical Sciences”.

Prof. Siepmann was visiting scientist/postdoctoral fellow at Purdue University, the University of Paris-Sud, the University of Iowa and the University of Angers.

Since 2010 he serves as president of the “International Society of Drug Delivery Sciences and Technology” (APGI) (Lien externe - Ouverture dans une nouvelle fenêtrehttps://www.apgi.org). The APGI was created in 1964 in Paris, and is an association for scientists in academia and industry, who are concerned with pharmaceutical technology and the design, formulation as well as biopharmaceutical and pharmacokinetic assessment of dosage forms and drug delivery systems.

Prof. Siepmann also serves as Editor-in-Chief of the “International Journal of Pharmaceutics” (IJP) (Lien externe - Ouverture dans une nouvelle fenêtrehttp://ees.elsevier.com/ijp) since 2016, publishing about 900 research and reviews articles per year in the field of Pharmaceutical Technology and Drug Delivery. Ii is a “top 1% journal” in the category “Pharmacology & Pharmacy” in terms of citation share (Web of Science, February 2020).

Currently, Prof. Siepmann is also the coordinator of the Interreg project “Site Drug: Site-Specific Drug Delivery” (Lien externe - Ouverture dans une nouvelle fenêtrehttps://www.interreg2seas.eu/fr/Site-Drug). The consortium counts 10 European Universities and companies. The aim is to develop innovative drug delivery systems for improved local drug treatments.

 

Main research interests

  • Preparation and physicochemical characterization of controlled drug delivery systems

  • Elucidation of the underlying drug release mechanisms from controlled drug delivery systems

  • Optimization of drug concentrations at the site of action in order to improve the efficacy of the therapeutical treatment and to minimize adverse effects
 





Page updated on 18/02/2020 (18h28)
 
Flux rss actualités